The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology
LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support.
XcellaraHeart™ is built on the Company's Xcellara™ base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation for XcellaraHeart's supply-side strategy: maintaining a healthy circulating pool of stem/progenitor-type cells.
The second component of the formula is Tanshinone IIA, a natural bioactive compound derived from Danshen root (Salvia miltiorrhiza). Tanshinone IIA has been studied in peer-reviewed cardiovascular research for its effects on the SDF-1α/CXCR4 chemokine axis, a signaling pathway linked to cellular trafficking, cardiovascular repair biology, and tissue-specific signaling.
XcellaraHeart™ was developed around a two-part cardiovascular-wellness strategy:
Supply: The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks.
Signaling: Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair-response biology.
"Traditional cardiovascular supplements often focus on circulation, antioxidant status, or vascular elasticity," said James Keener, CEO of BioAdaptives® Inc. "XcellaraHeart™ was developed to take a broader approach, combining the Xcellara™ stem/progenitor-cell mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its role in the SDF-1α/CXCR4 signaling pathways linked to cellular trafficking and cardiovascular wellness."
BioAdaptives® developed XcellaraHeart™ based on the hypothesis that increasing circulating stem/progenitor-type cells may be more meaningful when paired with nutrients that support tissue-specific signaling pathways. The Company believes Tanshinone IIA is a particularly compelling candidate for cardiovascular wellness because of its long research history and published evidence on cardiovascular signaling pathways.